Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Dose-Response Relationship: Selectivity and Specificity01:25

Dose-Response Relationship: Selectivity and Specificity

Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and β2-adrenergic receptors...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Variations in the latitudinal diversity gradients of the ocean microbiome.

Cell host & microbe·2026
Same author

microntology: a lightweight, data-driven controlled vocabulary to describe earth's microbial habitats.

Bioinformatics (Oxford, England)·2026
Same author

Molecular maps of diseases from omics data and network embeddings.

NPJ systems biology and applications·2026
Same author

CCMRI: a classification and curated database of climate change-related microbiome studies.

Scientific reports·2026
Same author

Estimating the economic burden of lower respiratory infections in China from 2020 to 2040: a health-augmented macroeconomic modelling study.

The Lancet regional health. Western Pacific·2026
Same author

Alcohol-related liver disease disrupts bile acid homeostasis and gut microbial bile acid metabolism.

JHEP reports : innovation in hepatology·2026
Same journal

Erratum for the Research Article "Detecting supramolecular organic nanoparticles during heat wave".

Science (New York, N.Y.)·2026
Same journal

Local signals, systemic decline.

Science (New York, N.Y.)·2026
Same journal

The mechanics of liver regeneration.

Science (New York, N.Y.)·2026
Same journal

Computing in a memory with physics.

Science (New York, N.Y.)·2026
Same journal

Retraction.

Science (New York, N.Y.)·2026
Same journal

Making time.

Science (New York, N.Y.)·2026
関連記事をすべて見る

関連する実験動画

Updated: Jul 3, 2026

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

副作用の類似性を用いて薬物標的の特定

Monica Campillos1, Michael Kuhn, Anne-Claude Gavin

  • 1European Molecular Biology Laboratory (EMBL), Meyerhofstrasse 1, 69117 Heidelberg, Germany.

Science (New York, N.Y.)
|July 16, 2008
PubMed
まとめ
この要約は機械生成です。

この研究は,薬剤の副作用が,化学的に異なった薬剤であっても,共通の薬剤標的を予測できることを明らかにしています. このアプローチは,新しい薬物標的相互作用と,既存の薬剤の潜在的な新しい治療用途を特定します.

さらに関連する動画

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction
05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

関連する実験動画

Last Updated: Jul 3, 2026

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction
05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

科学分野:

  • 薬理学 薬理学とは
  • コンピュータ生物学 コンピュータ生物学
  • ドラッグ・ディスカバリー・ドリッグ・ディスカバリー・ドリッグ・ディスカバリー・ドリッグ・ディスカバリー

背景:

  • 伝統的な薬物標的の予測は,化学構造や細胞系活動などの分子または細胞の特徴に依存しています.
  • 共通の薬物の標的を特定することは,薬物のメカニズムを理解し,薬物の再利用に不可欠です.

研究 の 目的:

  • 共通薬物標的を推論するために,フェノタイプの副作用類似性の有用性を調査する.
  • 新規の薬物対薬物関係,および潜在的薬物対標的相互作用を,販売中の薬物の大規模な分析を用いて発見すること.

主な方法:

  • 薬物関連ネットワークを構築するために,販売されている746の医薬品のフェノタイプの副作用の類似性を利用しました.
  • 予測された薬物対薬物関係と暗黙の薬物対標的相互作用は,インビトロ結合および細胞ベースの測定を用いて実験的に検証されました.

主要な成果:

  • 副作用による薬物関係1018のネットワークを特定し,そのうち261は異なる治療領域にわたる化学的に異なった薬を含む.
  • 13の暗黙の薬物標的関係が実験的に検証され,11の阻害定数は10マイクロモラー以下であった.
  • これらの相互作用の9つが細胞ベースのアッセイで確認され,現象型アプローチの可行性を実証しました.

結論:

  • フェノタイプの副作用の類似性は,分子相互作用と共通の薬物標的を推論するための実行可能な戦略です.
  • この方法は,予期せぬ薬物関連性を成功裏に特定し,新しい薬物標的相互作用を検証しました.
  • この発見は,現在市場に出されている既存の薬剤の新たな治療的応用の可能性を示唆している.